@FierceBiotech: Alnylam, Medicines Co. say next-gen PCSK9 drug has blockbuster potential. Article | Follow @FierceBiotech
@JohnCFierce: Amicus bags PhIII rare disease drug in $847M Scioderm buyout. News | Follow @JohnCFierce
@DamianFierce: Missed the FDA biosimilar-naming thing because vacation, but I'm a big fan of the phrase "suffix devoid of meaning." More | Follow @DamianFierce
> Purdue Pharma has signed a deal with Eisai to collaborate on the Japanese drugmaker's lemborexant, a Phase III insomnia treatment. More
> Bristol-Myers Squibb ($BMY) is joining forces with Australia's QIMR Berghofer Medical Research Institute to discover new antibodies in the field of immuno-oncology, looking to harness the body's natural defenses to fight malignancies. News
> Sweden's NeuroVive is backing away from its lead R&D program, developing the drug CicloMulsion for heart attack, after some disappointing Phase III results. The company now plans to focus on CicloMulsion's potential in acute kidney injury. Item
Medical Device News
@FierceMedDev: ICYMI Friday: Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive. More | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Updated $ABT's interest in $STJ w/ info from old article on their prior partnership. Neat to add context from 2012. Article | Follow @VarunSaxena2
@EmilyWFierce: $GOOG and $SNY are teaming up for #diabetes monitoring. More from the WSJ | Follow @EmilyWFierce
> Google pairs with Sanofi for diabetes monitoring collaboration. Story
> Precedent from Amarin's off-label promotion victory covers devices, too, especially those marketing a surrogate endpoint. Editor's Corner
> Philips debuts two new cardio products to European market at London conference. Article
Pharma News
@FiercePharma: ICYMI: Judge halts lawsuit blaming Purdue, Endo and others for epidemic of drug abuse. Article | Follow @FiercePharma
@EricPFierce: Majority of Mylan shareholders approve buyout of Perrigo, despite adamant opposition by its management. Press release | Follow @EricPFierce
@CarlyHFierce: 'No signal' of heart failure risk with Merck's Januvia, analysis confirms. Article | Follow @CarlyHFierce
> Dutch pension fund pulls out of Mylan amid death penalty drug concerns. Story
> Can Baxalta hold off Shire with its own bid for Ariad? More
> Patient education 'useless' when it comes to Eliquis adherence: study. Report
Animal Health News
> Denver cannabis seller teams with vet to launch pet wellness line. Item
> Cornell U spotlights veterinary profession on Nat Geo reality TV show. News
> Patterson shares fall on missed sales and earnings targets. More
> Young entrepreneur shows off veterinary product at White House Demo Day. Story
> Academic docs and biotechs partner with veterinarians to find cancer cures. Article
Biotech IT News
> Ginkgo Bioworks allies with Ajinomoto to expand into amino acid production. Item
> Venter's HLI nabs Millennium Health COO to oversee global expansion. Report
> Mytrus makes electronic informed consent breakthrough in U.K. Story
> How openFDA's 'crazy collision' of Silicon Valley and federal culture is reshaping the regulator. More
> UCL taps Elsevier resource to advance drug repurposing research. Article
Pharma Marketing News
> The 'Kardashian Effect' on pharma begs the question: Does social media influence drug requests? Story
> The need-to-know from ESC (so far): Merck, BMS, Pfizer and Sanofi. More
> Repatha vs. Praluent matchup has Amgen, Sanofi zeroing in on key details. Article
> Dutch pension fund dumps Mylan on worries about death penalty drug. Item
> Want to improve drug adherence, pharma? Get tracking. More